TAHO Pharma

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

35

Website

www.tahopharma.com

Country

Taiwan

Exchange

Taipei Exchange

Founded 2010

Taho Pharmaceuticals Ltd., a pharmaceutical company develops products using transdermal and transmucosal systems in Taiwan. Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting

TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia. It also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose TAH9922 Atomoxetine oral liquid and TAH9901 Methylphenidate patch for ADHD treatment. Founded in 2010, Taho Pharmaceuticals is based in Taipei, Taiwan.

Key Stats

52-Week Range

NT$61.50NT$208.50

Beta-0.11

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-4.16

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.